Clearmind Medicine Announces Publication of International Patent for Novel Therapy Targeting Weight Loss and Fatty Liver Disease
Rhea-AI Summary
Clearmind Medicine (Nasdaq: CMND) announced on March 10, 2026 the publication of an international PCT patent application for a novel, non-hallucinogenic combination therapy pairing MEAI with Palmitoylethanolamide (PEA) targeting weight loss and metabolic dysfunction-associated steatotic liver disease (MASLD).
The company cites a collaboration with NeuroThera Labs and notes market context: global weight-loss drugs valued at ~$37B in 2025 and forecast to reach ~$226B by 2035. The filing is a patent publication, not a granted patent or clinical efficacy readout.
Positive
- International PCT patent publication for MEAI-PEA combination (March 10, 2026)
- Collaboration established with NeuroThera Labs (PEA supplier) and SciSparc-linked partner
- Addresses large markets: obesity (~890 million adults) and MASLD (~30% adults)
- Cites weight-loss drugs market growth from $37B (2025) to $226B (2035)
Negative
- Patent application publication is not an issued patent or enforceable grant
- No clinical efficacy or safety results for the MEAI-PEA combination disclosed
- No financial terms or timelines for commercialization provided
News Market Reaction – CMND
On the day this news was published, CMND declined 1.96%, reflecting a mild negative market reaction. Argus tracked a peak move of +6.2% during that session. Argus tracked a trough of -18.9% from its starting point during tracking. Our momentum scanner triggered 12 alerts that day, indicating notable trading interest and price volatility. This price movement removed approximately $35K from the company's valuation, bringing the market cap to $2M at that time. Trading volume was elevated at 2.5x the daily average, suggesting increased selling activity.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
CMND fell 10.53% while selected biotech peers showed mixed moves: SXTP -3.98%, TTNP -3.96%, PLRZ -1.44%, KTTA +3.87%, SILO +8.27%. Momentum scanner flagged ADTX and SILO both moving down, indicating CMND’s decline appears more stock-specific than a broad sector move.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Mar 04 | Clinical trial update | Positive | -4.8% | DSMB unanimously cleared progression to third CMND-100 cohort with 80 mg dose. |
| Feb 19 | Promotional article | Positive | +4.2% | Paid review highlighted MEAI’s preclinical weight-loss data and patent activity. |
| Feb 09 | Clinical safety data | Positive | -8.2% | Additional positive topline safety results from second CMND-100 cohort in AUD trial. |
| Feb 06 | Development agreement | Positive | -6.9% | Agreement with Polyrizon to develop intranasal MEAI hydrogel formulation. |
| Feb 03 | Policy recognition | Positive | -5.8% | MEAI named in U.S. bill H.R. 7091 expanding veteran access to emerging therapies. |
Recent positive clinical and partnership updates have often been followed by negative price reactions, with only one of the last five news events aligning positively with the subsequent 24-hour move.
Over the past two months, Clearmind released a series of updates centered on its non-hallucinogenic MEAI platform. Clinical milestones included additional positive safety data and DSMB clearance to advance its FDA‑approved Phase I/IIa CMND‑100 trial for Alcohol Use Disorder on Feb 9 and Mar 4. Strategically, the company announced an intranasal MEAI formulation agreement and legislative recognition of MEAI on Feb 3 and Feb 6, plus a promotional review of MEAI’s weight‑loss potential on Feb 19. Despite largely positive news, four of these five events saw negative next‑day price reactions.
Market Pulse Summary
This announcement details an international PCT patent application for a MEAI‑PEA combination targeting obesity and MASLD, conditions affecting over 890 million people and roughly 30% of adults, respectively. It extends Clearmind’s MEAI platform beyond alcohol use disorder into a weight-loss and liver-disease market projected to surpass $200 billion by 2035. In context of recent clinical and financing updates, investors may watch for concrete development plans, regulatory interactions, and early human data to assess how this concept translates into a pipeline asset.
Key Terms
metabolic dysfunction-associated steatotic liver disease medical
MASLD medical
Patent Cooperation Treaty (PCT) regulatory
Palmitoylethanolamide medical
neuroplastogen medical
GLP-1s agonists medical
AI-generated analysis. Not financial advice.
Innovative non-hallucinogenic treatment combines MEAI with Palmitoylethanolamide to address obesity and metabolic dysfunction-associated steatotic liver disease, tapping into a rapidly growing market projected to exceed
Vancouver, Canada, March 10, 2026 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the "Company"), a clinical-stage biotech company focused on the discovery and development of novel, non-hallucinogenic, second generation, neuroplastogen-derived therapeutics to solve major under-treated health problems, today announced the publication of an international patent application under the Patent Cooperation Treaty (PCT) for a novel combination therapy aimed at treating weight loss and metabolic dysfunction-associated steatotic liver disease (MASLD, formerly known as fatty liver disease). This novel therapy integrates Clearmind’s proprietary 5-methoxy-2-aminoindane (MEAI) with Palmitoylethanolamide (PEA), provided through its collaboration with NeuroThera Labs Inc. (TSXV: NTLX), a subsidiary of SciSparc Ltd. (Nasdaq: SPRC).
The patent publication highlights the potential of this MEAI-PEA combination to offer a safe, non-hallucinogenic neuroplastogen treatment for two major global health challenges: obesity, affecting over 890 million adults worldwide, and MASLD, impacting approximately
"The publication of this international patent is part of our mission to develop innovative, proprietary and transformative therapies for underserved metabolic and neurological conditions," said Dr. Adi Zuloff-Shani, CEO of Clearmind Medicine. "By combining our MEAI platform with PEA from our partners at NeuroThera Labs, we are positioning ourselves to address the escalating demand for effective, tolerable and safe treatments in the obesity and liver health space. This comes at a time when the global weight loss drugs market is experiencing rapid growth, which was valued at approximately
About Clearmind Medicine Inc.
Clearmind is a clinical-stage neuroplastogens pharmaceutical biotech company focused on the discovery and development of novel psychedelic-derived therapeutics to solve widespread and underserved health problems, including alcohol use disorder. Its primary objective is to research and develop psychedelic-based compounds and attempt to commercialize them as regulated medicines, foods, or supplements.
The Company’s intellectual portfolio currently consists of nineteen patent families, including 31 granted patents. The Company intends to seek additional patents for its compounds whenever warranted and will remain opportunistic regarding the acquisition of additional intellectual property to build its portfolio.
Shares of Clearmind are listed for trading on Nasdaq under the symbol "CMND".
For further information, visit: https://www.clearmindmedicine.com or contact:
Investor Relations
invest@clearmindmedicine.com
Telephone: (604) 260-1566
US: CMND@crescendo-ir.com
General Inquiries
Info@Clearmindmedicine.com
www.Clearmindmedicine.com
Forward-Looking Statements:
This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act and other securities laws. Words such as “expects,” “anticipates,” “intends,” “plans,” “believes,” “seeks,” “estimates” and similar expressions or variations of such words are intended to identify forward-looking statements. For example, the Company is using forward-looking statements when it discusses the potential of this MEAI-PEA combination to offer a safe, non-hallucinogenic neuroplastogen treatment for obesity and MASLD, its mission to develop innovative, proprietary and transformative therapies for underserved metabolic and neurological conditions, how this therapeutic option may offer a safer, easier and more cost effective option than GLP-1s agonists for obesity and MASLD, how it is position itself to address the escalating demand for effective, tolerable treatments in the obesity and liver health space and the expected growth of the global weight loss drugs market.
Forward-looking statements are not historical facts, and are based upon management’s current expectations, beliefs and projections, many of which, by their nature, are inherently uncertain. Such expectations, beliefs and projections are expressed in good faith. However, there can be no assurance that management’s expectations, beliefs and projections will be achieved, and actual results may differ materially from what is expressed in or indicated by the forward-looking statements. Forward-looking statements are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed in the forward-looking statements. For a more detailed description of the risks and uncertainties affecting the Company, reference is made to the Company’s reports filed from time to time with the Securities and Exchange Commission (“SEC”), including, but not limited to, the risks detailed in the Company’s annual report on Form 20-F for the fiscal year ended October 31, 2025 and subsequent filings with the SEC. Forward-looking statements speak only as of the date the statements are made. The Company assumes no obligation to update forward-looking statements to reflect actual results, subsequent events or circumstances, changes in assumptions or changes in other factors affecting forward-looking information except to the extent required by applicable securities laws. If the Company does update one or more forward-looking statements, no inference should be drawn that the Company will make additional updates with respect thereto or with respect to other forward-looking statements. References and links to websites have been provided as a convenience, and the information contained on such websites is not incorporated by reference into this press release. Clearmind is not responsible for the contents of third-party websites.
FAQ
What did Clearmind (CMND) announce on March 10, 2026 about a new patent?
How does the new MEAI-PEA patent impact Clearmind's CMND development strategy?
Does the Clearmind (CMND) announcement include clinical trial results for MEAI-PEA?
What market size did Clearmind cite for weight-loss drugs in the CMND release?
Is the published PCT application equivalent to a granted patent for Clearmind (CMND)?
